Topiramate Monotherapy for Civilian Posttraumatic Stress Disorder: A Controlled Pilot Study

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Posttraumatic stress disorder (PTSD) is a debilitating condition requiring effective treatments.
• Topiramate is an anticonvulsant medication with potential neuropsychiatric applications.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of topiramate in civilian adults diagnosed with PTSD.
• To compare topiramate's effects against a placebo over a 12-week treatment period.

Main Methods:

• A 12-week, double-blind, randomized, placebo-controlled study involving 72 outpatients with PTSD.
• Efficacy assessed via Clinician-Administered PTSD Scale (CAPS) scores; safety monitored through adverse events and clinical assessments.

Main Results:

• Topiramate demonstrated a greater percentage reduction in CAPS scores (39.5%) compared to placebo (29.5%), though not statistically significant (P=.31).
• Trends favored topiramate in CAPS subscale scores for reexperiencing, avoidance/numbing, and hyperarousal symptoms, but lacked statistical significance.
• Fewer patients in the topiramate group experienced AE-related discontinuation compared to placebo (18% vs 26%).

Conclusions:

• Topiramate showed a trend towards improving PTSD symptoms compared to placebo in this civilian cohort.
• While generally well-tolerated, the observed differences did not achieve statistical significance.
• Further adequately powered studies are recommended to confirm topiramate's efficacy in PTSD treatment.